Calf diarrhea causes substantial economic losses to beef cattle production worldwide. It is a complex multifactorial pathological condition influenced by infectious, nutritional and environmental factors. The present study focused on analyzing the pathological and molecular characterization of bovine rotavirus A (BoRVA) during a diarrhea outbreak in a beef cattle herd located in the state of Mato Grosso, central-western region, Brazil. The outbreak caused high morbidity (80%) and mortality (12%) among 1,100 calves up to 30 days of age. The BoRVA was identified in 53.3% (16/30) of the diarrheic fecal samples analyzed using the silver-stained polyacrylamide gel electrophoresis (ss-PAGE) technique. The nucleotide sequence analysis of VP7 (G genotype) and VP4 (P genotype) via RT-PCR from eight BoRVA-positive fecal samples showed the genotypes G6P[5] (n = 6), G6P[11] (n = 1) and G6P[X] (n = 1). Three calves were necropsied and the gross findings included edema and thickened, wrinkled bowel mucosa in the small intestine. Microscopic lesions were confined to the villi of the small intestine, characterized mainly by villus fusion and moderate multifocal lymphoplasmacytic enteritis. Immunohistochemical examination of three cases was positive for BoRVA. The 53.3% of the diarrheic fecal samples that were positive for BoRVA in this study suggested that RV was the etiological agent involved in this neonatal calf diarrhea outbreak.
Background and Aim: Canine visceral leishmaniasis (CanL) has a broad spectrum of changes, with kidney disease being considered the main cause of mortality. Thus, this study aimed to monitor serum and urinary biomarkers in response to two short-term treatments for CanL. Materials and Methods: Thirty dogs with CanL were equally divided into two treatment groups and treated with either miltefosine (Group M) or miltefosine plus allopurinol (Group MA); the groups were evaluated before treatment and after 28 days of treatment. Physical exams were performed and hematimetric, biochemical, and urinary parameters, including urinary biomarkers cystatin C (CisC), lipocalin-2 (NGAL), and microalbuminuria, were measured. Results: Both treatments significantly reduced clinical scores (p<0.05), but only the MA group saw a reduction in the clinical-pathological score. The serum albumin and calcium levels increased significantly in the MA and M groups (p<0.05). Proteinuria and urinary density did not decrease significantly after the treatments. With regard to the biomarkers, CisC and microalbuminuria did not have any significant changes; however, NGAL was significantly reduced in the MA group (p<0.05). Conclusion: Both pharmacotherapeutic protocols promoted clinical and clinical-pathological improvements. In addition, miltefosine plus allopurinol proved to be a safe treatment due to the lack of changes detected in the monitored renal biomarkers. The treatment with miltefosine plus allopurinol proved to be the most effective, with more pronounced beneficial effects for canines with visceral leishmaniasis.
Canine visceral leishmaniasis is an endemic zoonosis in Brazil. Dogs are the main hosts in urban environments. The treatment has gained popularity since the Brazilian government authorized miltefosine for canine treatment. The aim of this study was to investigate the clinical and parasitological impact of short-term treatment with miltefosine and allopurinol, alone and in combination. We evaluated the ability of pharmacotherapy to reduce clinical signs of disease, antibody levels using the indirect fluorescence antibody test (IFAT) and skin parasite load via qPCR after 28 days of treatment. The therapeutic protocols promoted a significant decline in clinical signs and in the skin parasite load in dogs (p < 0.01). We observed a moderate correlation between the skin parasite load and the clinical score in all three treatment groups (r > 0.5) Antibody levels did not decrease in this short period. It was concluded that the treatment with allopurinol reduced the number of parasites in the skin of dogs with visceral leishmaniasis in the short term. However, its efficiency is potentiated when associated with miltefosine.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.